Stay updated on Pembrolizumab for Lung Cancer Prevention Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Lung Cancer Prevention Clinical Trial page.

Latest updates to the Pembrolizumab for Lung Cancer Prevention Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has undergone significant updates, including the removal of detailed information about a phase II trial studying pembrolizumab for lung cancer prevention, while adding new classifications for lung cancer stages and registry identifiers.SummaryDifference61%
- Check29 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to February 20, 2025.SummaryDifference0.3%
- Check37 days agoChange DetectedThe page has been updated to reflect the latest version as v2.14.3, with the last update date changed to March 25, 2025. The previous version, v2.14.2, and its update date of February 20, 2025, have been removed.SummaryDifference0.2%
- Check73 days agoChange DetectedThe page has updated the study details for the IMPRINT-Lung study, including a new estimated last update date of February 2025 and a change in the principal investigator's contact information. Additionally, the previous estimated recruitment date has been removed.SummaryDifference3%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.9%
Stay in the know with updates to Pembrolizumab for Lung Cancer Prevention Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Lung Cancer Prevention Clinical Trial page.